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The measurement of enzymes in blood, other body fluids and cells is now a firmly established part of laboratory medicine and health science. The large number of such measurements which are carried out daily in the clinical laboratories of the world are almost exclusively measurements of the catalytic activity concentration of the enzymes under study. Although immunological measurements have advantages in certain circumstances, such as cancer detection, particularly in view of the possibilities opened up by monoclonal antibodies, measurement of catalytic activity has the advantages of very great sensitivity and specificity for the enzyme being determined. Such measurements can be performed rapidly, with relatively low reagent costs. On the other hand, the numerical results of catalytic activity measurements depend entirely on the experimental conditions under which the measurements are made. Thus, it is often difficult to compare enzyme results obtained in different laboratories, or reported in the scientific literature, or to assess the analytical performance of different laboratories.
The problem of the method-dependence and lack of comparability of enzyme activity measurements has been addressed by national and international societies for clinical chemistry, which have recommended reliable methods of determination, incorporating current knowledge. There is no doubt that this approach has met with considerable success in hastening the elimination of unsatisfactory methods and irn-proving inter-laboratory comparability. External quality assessment schemes show that laboratories using the same recommended methods are able to agree regularly on the results for enzyme activity of survey specimens with coefficients of variation of less than 10%, i.e. of the same order of magnitude as for nonenzymic analysis. But what happens over a long period of determination to the long-term analytical variability?
However, complete uniformity of methods of enzyme analysis has not been obtained, nor is such uniformity attainable or even desirable. Several different national recommendations are in force, representing adaptations to local circumstances. Similarly, new developments in methodology and instrumentation will continue to introduce new techniques into clinical enzymology. Furthermore, small changes in the quality or concentrations of the reagents are made by manufacturing companies without advising users. Even when a method is apparently unchanged over a period of time, small changes may become incorporated imperceptibly, leading to altered analytical performance.
In order to ensure that the successes of the recommended method approach are preserved, and to prevent a drift back to a profusion of unrelated methods of enzyme analysis, enzyme reference materials are needed through which the results of secondary or modified enzyme methods can be traced back to a recognised primary method, such as an internationally recommended method.
The required characteristics of suitable enzyme reference material include tested and predictable stability of catalytic activity, and an activity in the selected method (or methods) which is assured within defined limits. Catalytic properties of the reference material must be as close as possible to those of the human serum enzyme. Matrix effects must be explored and controlled. Although in practice criteria of purity cannot be laid down for enzyme materials as they can for simpler substances, the preparation and properties of an enzyme reference material should be defined sufficiently closely to allow successive batches to be prepared with consistent properties. In the near future it may become possible to produce consistent batches of an enzyme preparation by application of the techniques of gene cloning.
When available, an enzyme reference material has several potential uses: first, to test the ability of laboratories to recover the assigned value within a chosen limit when using the same method. Second, taking into account a correlation factor, the preparation can be used to test the ability to recover the expected value when a method similar in principle, but different in conditions, is used. For example, the different method may be a nationally or regionally recommended method. Before a preparation is used in this way, however, the relationship between the primary and secondary method must be carefully established by experiment. Third, the reference preparation may be used to verify the activities of secondary, enzyme preparations of the kind which are produced in large quantities for day-to-day quality control purposes. However, this kind of application is by no means a 'standardisation' based on values given by the reference method.
The need for 'stable enzyme preparation of known activity' in analysis was pointed out by Moss' in 1971. Rej, Vanderlinde and Fasce/ reported on aspartate aminotransferase from human erythrocytes as a reference material, and Fasce et al.•3 stated the specifications which enzyme materials may be required to meet. Since then, other workers have prepared purified enzyme materials and used them in the inter-laboratory evaluation of reference methods or to establish inter-method relationships; e.g. aspartate arninotransferase.f lactate dehydrogenase," amylase," alkaline phosphatase?' 8 and acid phosphatase."
Specifications and functions of reference materials have also been described by Horder and RejlO and their use in clinical enzymology by Beacham, Whitaker and Moss.'! Substantially the same problems were encountered in pharmaceutical enzymology.
International standardisation procedures for pharmaceutical enzymes and their assay have been in common use since 1960. These achievements were obtained by the FIP Enzyme Commission of the Federation Internationale Pharmaceutique (FIP). The FIP methods, 12 units13 and enzyme reference materials for trypsin, chymotrypsin and pancreatin (lipase, protease and amylase) have been adopted by the European Pharmacopoeia.
In 1980, the Community Bureau of Reference of the European Community (BCR) established a working group of clinical enzymologists to prepare and evaluate reference preparations of enzymes of diagnostic importance. Gamma-glutamyltransferase (GGT) was chosen as the first enzyme to be studied essentially because of its known stability'? and properties.Pr" and because of its widespread use in clinical laboratories. A preparation of pig-kidney GGT, partially hydrolysed with papain, was prepared and lyophilised in a matrix containing bovine serum albumin. The pig-kidney enzyme was shown to be very similar to human serum GGT in catalytic characteristics such as Michaelis constants for the substrates gamma-glutamyl-carboxynitroanilide and glycyl-glycine, pH optimum, etc. 21 When placed in ampoules or vials, the activity was essentially stable as predicted by accelerated degradation tests. The predicted degradation at -20"C is 0·01 % per year with an approximate 95% limit of less than 0·1 % per year.
The IFCC method'" was chosen to assign the activity of the reference preparation. Results from 11 participating laboratories indicated a mean value of 236·8 U/L with a coefficient of variation of 3·4%. These narrow limits are evidence not only of the uniformity and stability of the GGT preparation, but also of the transferability of the IFCC reference method.
The GGT preparation has been submitted to inter-laboratory trials to establish the relationship between its activity determined by the IFCC method, and its activities measured by several nationally recommended methods, e.g., SCE (Nordic countries), SFBC (France) and ACB (UK). The relative activities by the several methods have simultaneously been determined for large numbers of patients' serum samples. The ratio of the activities of the GGT preparation for the various pairs of methods (SCE:IFCC, SFBC:IFCC, etc.) differs in each case by less than 5% from the corresponding average ratio for patient's serum samples. Studies of this type are essential in establishing the property which has been termed "commutability'.
The working group of BCR is now establishing protocols for the preparation and evaluation of other reference materials. Because of their clinical importance, preparations of creatine kinase, alkaline phosphatase, and alanine and aspartate aminotransferases will be given priority. Together with the GGT preparation" such preparations, with their assured stabilities and closely-specified activities, will be of great value to clinical scientists and manufacturers of diagnostic reagents not only in the European Community but also in other countries.
